SOHO 2022 | Managing relapse post-CAR-T therapy in DLBCL & the need to change clinical trial inclusion criteria
Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MI, talks on available and emerging strategies to manage patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CAR-T therapy. Dr Nowakowski first highlights the need to change clinical trial inclusion criteria to increase the number of relapsed/refractory (R/R) patients who can participate in these studies, explaining that it is also important to avoid myelosuppressive agents in these patients. In addition, Dr Nowakowski outlines different strategies that have shown promising efficacy in patients who relapse after CAR-T therapy, including polatuzumab vedotin, bendamustine and rituximab (Pola-BR), lenalidomide, tafasitamab, selinexor, and loncastumixab tesirine (Lonca-T). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
